{"result": "(\"entity\"<|>VENLAFAXINA<|>ORGANIZATION<|>Venlafaxina is a serotonin and norepinephrine reuptake inhibitor that may cause an increase in prolactin levels in some patients.)\n##\n(\"entity\"<|>BUPROPION<|>ORGANIZATION<|>Bupropion is a norepinephrine and dopamine reuptake inhibitor that does not appear to affect prolactin levels.)\n##\n(\"entity\"<|>VERAPAMILO<|>ORGANIZATION<|>Verapamil is a calcium antagonist that can cause hyperprolactinemia in up to 8.5% of users, though the mechanism is unknown.)\n##\n(\"entity\"<|>RISPERIDONA<|>ORGANIZATION<|>Risperidone is a second-generation antipsychotic associated with frequent and marked increases in prolactin levels.)\n##\n(\"entity\"<|>AMISULPIRIDA<|>ORGANIZATION<|>Amisulpride is a second-generation antipsychotic that is also linked to significant increases in prolactin levels.)\n##\n(\"entity\"<|>ANTIPSICOTICOS<|>ORGANIZATION<|>Antipsychotics are the most common pharmacological cause of hyperprolactinemia, particularly first-generation antipsychotics.)\n##\n(\"entity\"<|>HIPERPROLACTINEMIA<|>EVENT<|>Hyperprolactinemia is a condition characterized by elevated levels of prolactin in the blood, often caused by certain medications or physiological conditions.)\n##\n(\"entity\"<|>SINDROME DE CUSHING<|>EVENT<|>Cushing's syndrome is a condition caused by chronic exposure to high levels of cortisol, often due to a pituitary tumor producing ACTH.)\n##\n(\"entity\"<|>ACTH<|>ORGANIZATION<|>Adrenocorticotropic hormone (ACTH) is a hormone produced by the pituitary gland that stimulates the adrenal glands to produce cortisol.)\n##\n(\"entity\"<|>HORMONAS<|>ORGANIZATION<|>Hormones are regulatory substances produced in organisms to stimulate specific cells or tissues into action.)\n##\n(\"entity\"<|>CORTISOL<|>ORGANIZATION<|>Cortisol is a steroid hormone produced by the adrenal glands, often referred to as the stress hormone.)\n##\n(\"relationship\"<|>RISPERIDONA<|>HIPERPROLACTINEMIA<|>Risperidone is associated with frequent and marked increases in prolactin levels, contributing to hyperprolactinemia<|>8)\n##\n(\"relationship\"<|>AMISULPIRIDA<|>HIPERPROLACTINEMIA<|>Amisulpride is linked to significant increases in prolactin levels, contributing to hyperprolactinemia<|>8)\n##\n(\"relationship\"<|>ANTIPSICOTICOS<|>HIPERPROLACTINEMIA<|>Antipsychotics are the most common pharmacological cause of hyperprolactinemia<|>9)\n##\n(\"relationship\"<|>VENLAFAXINA<|>HIPERPROLACTINEMIA<|>Venlafaxina may cause an increase in prolactin levels in some patients, contributing to hyperprolactinemia<|>6)\n##\n(\"relationship\"<|>BUPROPION<|>HIPERPROLACTINEMIA<|>Bupropion does not appear to affect prolactin levels, thus it is not a cause of hyperprolactinemia<|>1)\n##\n(\"relationship\"<|>VERAPAMILO<|>HIPERPROLACTINEMIA<|>Verapamil can cause hyperprolactinemia in up to 8.5% of users<|>5)\n##\n(\"relationship\"<|>SINDROME DE CUSHING<|>ACTH<|>Cushing's syndrome is often caused by a pituitary tumor producing ACTH, leading to elevated cortisol levels<|>7)\n##\n(\"relationship\"<|>CORTISOL<|>SINDROME DE CUSHING<|>Cortisol is the hormone that is chronically elevated in Cushing's syndrome<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: COMENTARIO\n\nDentro de las causas farmacológicas de hiperprolactinemia, los antipsicóticos son la causa más habitual. Aunque son los antipsicóticos de primera generación los que causan más elevación de PRL (en relación con un mayor bloqueo de los receptores D2 dopaminérgicos), algunos de segunda generación, como la risperidona o la amisulpirida se asocian a frecuentes y marcados aumentos de PRL (respuesta D).\n\nLa venlafaxina es un inhibidor de la recaptación de serotonina y noradrenalina. Existen algunas publicaciones que refieren cierto aumento de PRL con venlafaxina, aunque no ocurre en todos los pacientes. También se ha descrito galactorrea y dolor mamario (respuesta C).\n\nEl bupropión, un inhibidor de la recaptación de noradrenalina y dopamina, no parece afectar a los niveles de PRL (respuesta A).\n\nDentro de los antagonistas del calcio, el verapamilo produce hiperprolactinemia hasta en un 8,5% de los usuarios, aunque se desconoce el mecanismo (respuesta B).\n\nReferencias:\n- Coker F, Taylor D. Antideppresant-induced Hyperprolactinemia: Incidence, Mechanisms and Management. CNS Drugs. 2010;24(7):563-74.\n- Snyder PJ. Causes of hyperprolactinemia. En: Cooper DS, Martin KA, eds. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (acceso 29 de abril de 2019).\n\n## 36. Todas las situaciones siguientes pueden aumentar los niveles de PRL excepto una:\n\nA. Traumatismo de pared torácica.\nB. Insuficiencia renal crónica.\nC. Tratamiento con metoclopramida.\nD. Tratamiento con lisurida.\n\n### COMENTARIO\n\nEl aumento de los niveles de PRL puede ser:\n\n- Fisiológico: en situaciones como el embarazo, la lactancia, el coito, el sueño, ejercicio o el estrés.\n- Farmacológico: en relación con fármacos psiquiátricos (antipsicóticos, antidepresivos, etc.), pero también otros como los antieméticos (metoclopramida) (respuesta C) (véase comentario de la pregunta 27).\n- Patológico: entre los que se incluirían el aumento de PRL por mecanismo neural, como en las lesiones de la pared torácica (respuesta A), o por disminución del aclaramiento como en la enfermedad renal crónica (respuesta B) (v. tabla 3 en comentario de la pregunta 27).\n\nPor el contrario, la lisurida es un agonista dopaminérgico que reduce los niveles de PRL y es una de las opciones en el tratamiento médico de la hiperprolactinemia junto con otros agonistas dopaminérgicos como la bromocriptina, la cabergolina o la quinagolida (opción D falsa).\n\nReferencias:\n- Villar-Taibo R, Sifontes-Dubon M, Bernabeu-Moron I, Casanueva FF. Prolactin excess and deficiency: Epidemiology, causes (excluding prolactin-secreting pituitary tumors). En: Tritos NA, Klibansky A, eds. Prolatin disorders. From basic science to clinical management. 1.ª ed. Springer Nature Switzerland AG: Humana Press; 2019.\n---\n# HIPÓFISIS\n\n## 1.6 Síndrome de Cushing\n\n### 37. Con respecto a los tumores hipofisarios causantes de síndrome de Cushing, señale la respuesta correcta:\n\nA. La RMN es menos sensible que la TAC para detectar adenomas productores de ACTH.\nB. La RMN solo detecta alrededor del 50% de estos tumores.\nC. La TAC puede orientar sobre la funcionalidad de un adenoma hipofisario.\nD. Todas las respuestas anteriores son falsas.\n\n#### COMENTARIO\n\nDiagnóstico del síndrome de Cushing\n\nEl síndrome de Cushing se asocia a la exposición crónica a niveles elevados de cortisol en el organismo. Su diagnóstico requiere tres pasos:\n\n1. Sospecha clínica de hipercortisolismo: en función de los síntomas y signos del paciente.\n2. Confirmación del hipercortisolismo.\n3. Determinación de la etiología del hipercortisolismo: ACTH dependiente, independiente o yatrogénica.\n\nCuando la causa del síndrome de Cushing es un tumor hipofisario productor de ACTH se denomina enfermedad de Cushing.\n\nTécnicas de imagen en la enfermedad de Cushing\n\nCuando las pruebas orientan a la existencia de una enfermedad de Cushing, se debe solicitar una RMN hipofisaria. La RMN es más sensible que la TAC para detectar adenomas corticotropos, pero aun así solo detecta el 50% de estos tumores (respuesta A falsa y respuesta B correcta). La imagen en TAC no diferencia la funcionalidad de un\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}